Tumour-selective drug delivery via folate receptor-targeted liposomes

Expert Opinion on Drug Delivery

Volumn 1, Issue 1, 2004, Pages 7-17

  Pan, Xiaogang ^a   Lee, Robert J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Antisense oligodeoxyribonucleotides; Chemotherapy; Folate receptor; Gene therapy; Liposome; Multi drug resistance; Targeted drug delivery

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CALCEIN; CHOLESTEROL HYDROGEN SUCCINATE; CYTARABINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; FOLATE RECEPTOR; FOLIC ACID; GLYCOPROTEIN P; HAPTEN; LIPOPLEX; LIPOSOME; MACROGOL 2000; MACROGOL 3350; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PENTETATE INDIUM IN 111; PLASMID DNA; RADIOPHARMACEUTICAL AGENT; RETINOIC ACID; T LYMPHOCYTE ANTIBODY; TAMOXIFEN; TETRASULFOPHTHALOCYANINE CHLOROALUMINUM;

ANTINEOPLASTIC ACTIVITY; ASCITES TUMOR; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; CYTOTOXICITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; GENE TARGETING; GENE TRANSFER; GENETIC TRANSFECTION; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MULTIDRUG RESISTANCE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OVARY CARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; HUMANS; LIPOSOMES; NEOPLASMS; RECEPTORS, CELL SURFACE;

EID: 14544300545     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.1.1.7     Document Type: Review

References (90)

1. General review of the recent work in immunity. Ehrlich PA (Ed.), Pergamon Press, London, UK (1956).
2. BANGHAM AD, STANDISH MM, WATKINS JC: Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. (1965) 13(1):238-252.
3. GABIZON A, MARTIN F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs (1997) 54(Suppl. 4):S15-S21.
4. FELGNER PL, RINGOLD GM: Cationic liposome-mediared transfection. Nature (1989) 337(6205):387-388.
5. GAO X, HUANG L: A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. (1991) 179(1):280-285.
6. REDDY R, ZHOU F, HUANG L et al.: pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. J. Immunol. Methods (1991) 141(2):157-163.
7. YATVIN MB, KREUTZ W, HORWITZ BA, SHINITZKY M: pH-sensitive liposomes - possible clinical implications. Science (1980) 210 4475):1253-1254.
8. LOPES DE MENEZES DE, PILARSKI LM, ALLEN TM: In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. (1998) 58(15):3320-3330.
9. LESERMAN LD, MACHY P, BARBET J: Cell-specific drug transfer from liposomes bearing monoclonal antibodies. Nature (1981) 293 5829):226-228.
10. WANG S, LEE RJ, CAUCHON G, GORENSTEIN DG, LOW PS: Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA (1995) 92(8):3318-3322.
11. SINGH M: Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des. (1999) 5(6):443-451.
12. LEE RJ, LOW PS: Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. (1994) 269(5):3198-3204.
13. VOET D: Biochemistry (Vol. 1) Chapters 1-19. Donald Voet, Judith G, Voet JG (Eds) Wiley, New York, USA (2003):1200.
14. SUDIMACK J, LEE RJ: Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. (2000) 41(2):147-162.
15. LU Y, LOW PS: Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. (2002) 54 5):675-693.
16. GOSSELIN MA, LEE RJ: Folate receptor-targeted liposomes as vectors for therapeutic agents. Biotechnol Ann. Rev. (2002) 8 103-131.
17. GABIZON A, SHMEEDA H, HOROWITZ AT, ZALIPSKY S: Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. (2004) 56 8):1177-1192.
18. LEAMON CP, REDDY JA: Folate-targeted chemotherapy. Adv. Drug Deliv. Rev. (2004) 56(8):1127-1141.
19. ELWOOD PC: Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J. Biol. Chem. (1989) 264 25):14893-14901.
20. LACEY SW, SANDERS JM, ROTHBERG KG, ANDERSON RG, KAMEN BA: Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosylphosphatidylinositol. J. Clin. Invest. (1989) 84(2):715-720.
21. RATNAM M, MARQUARDT H, DUHRING JL, FREISHEIM JH: Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry (1989) 28(20):8249-8254.
22. ANTONY AC: Folate receptors. Ann. Rev Nutr. (1996) 16:501-521.
23. SHEN F, WU M, ROSS JF, MILLER D, RATNAM M: Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry (1995) 34(16):5660-5665.
24. SHEN F, ROSS JF, WANG X, RATNAM M: Identification of a novel folate receptor, a truncated receptor, and receptor type beta in haematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry (1994) 33(5):1209-1215.
25. MAZIARZ KM, MONACO HL, SHEN F, RATNAM M: Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta. J. Biol. Chem. (1999) 274 16):11086-11091.
26. WANG X, SHEN F, FREISHEIM JH, GENTRY LE, RATNAM M: Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem. Pharmacol. (1992) 44(9):1898-1901.
27. SHEN F, ZHENG X, WANG J, RATNAM M: Identification of amino acid residues that determine the differential ligand specificities of folate receptors alpha and beta. Biochemistry (1997) 36 20):6157-6163.
28. GARIN-CHESA P, CAMPBELL I, SAIGO PE et al.: Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. (1993) 142(2):557-567.
29. ROSS JF, WANG H, BEHM FG et al.: Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer (1999) 85(2):348-357.
30. ROSS JF, CHAUDHURI PK, RATNAM M: Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer (1994) 73(9):2432-2443.
31. WEITMAN SD, WEINBERG AG, CONEY LR et al.: Cellular localization of the folate receptor potential role in drug toxicity and folate homeostasis. Cancer Res. (1992) 52(23):6708-6711.
32. WU M, GUNNING W, RATNAM M: Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. (1999) 8 9):775-782.
33. WEITMAN SD, LARK RH, CONEY LR et al.: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. (1992) 52(12):3396-3401.
34. NAKASHIMA-MATSUSHITA N, HOMMA T, YU S et al.: Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. (1999) 42(8):1609-1616.
35. PAN XQ, ZHENG X, SHI G et al.: Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood (2002) 100(2):594-602.
36. CORROCHER R, BAMBARA LM, PACHOR ML et al.: Serum folate binding capacity in leukemias, liver diseases and pregnancy. Acta Haematol. (1979) 61(4):203-208.
37. GUO W, HINKLE GH, LEE RJ: 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J. Nucl. Med. (1999) 40(9):1563-1569.
38. LEAMON CP, PASTAN I, LOW PS: Cytotoxicity of folate- Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J. Biol. Chem. (1993) 268 33):24847-24854.
39. LEAMON CP, COOPER SR, HARDEE GE: Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem. (2003) 14 4):738-747.
40. LU JY, LOWE DA, KENNEDY MD, LOW PS: Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J. Drug Target. (1999) 7(1):43-53.
41. KRANZ DM, PATRICK TA, BRIGLE KE, SPINELLA MJ, ROY EJ: Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. USA (1995) 92(20):9057-9061.
42. KONDA SD, AREF M, WANG S, BRECHBIEL M, WIENER EC: Specific targeting of folate dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magma (2001) 12(2-3):104-113.
43. MOON WK, LIN Y, O'LOUGHLIN T et al.: Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate. Bioconjug. Chem. (2003) 14(3):539-545.
44. SHUKLA S, WU G, CHATTERJEE M et al.: Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug. Chem. (2003) 14(1):158-167.
45. LU Y, LOW PS: Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. (2002) 51(3):153-162.
46. LEE RJ, HUANG L: Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem. (1996) 271(14):8481-8487.
47. OYEWUMI MO, MUMPER RJ: Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folate-coated nanoparticles. Int. J. Pharm. (2003) 251(1-2):85-97.
48. LEAMON CP, LOW PS: Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov. Today (2001) 6(1):44-51.
49. LEAMON CP, LOW PS: Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA (1991) 88(13):5572-5576.
50. LEE RJ, WANG S, LOW PS: Measurement of endosome pH following folate receptor-mediated endocytosis. Biochim. Biophys. Acta (1996) 1312(3):237-242.
51. RIJNBOUTT S, JANSEN G, POSTHUMA G et al.: Endocytosis of GPI-linked membrane folate receptor-alpha. J. Cell Biol. (1996) 132(1-2):35-47.
52. CHRISTENSEN EI, BIRN H, VERROUST P, MOESTRUP SK: Membrane receptors for endocytosis in the renal proximal tubule. Int. Rev. Cytol. (1998) 180:237-284.
53. SAUL JM, ANNAPRAGADA A, NATARAJAN JV, BELLAMKONDA RV: Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control. Release (2003) 92(1-2):49-67.
54. LEE RJ, LOW PS: Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta (1995) 1233(2):134-144.
55. GUO WJ, LEE T, SUDIMACK J, LEE RJ: Receptor-specific delivery of liposomes via folate-PEG-Chol. J. Liposome Res. (2000) 10 2-3):179-195.
56. GABIZON A, HOROWITZ AT, GOREN D et al.: Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. (1999) 10(2):289-298.
57. UDIMACK JJ, GUO W, TJARKS W, LEE RJ: A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim. Biophys. Acta (2002) 1564(1):31-37.
58. QUALLS MM, THOMPSON DH: Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: intracellular localization and synergistic phototoxicity. Int. J. Cancer (2001) 93(3):384-392.
59. GOTTESMAN MM, FOJO T, BATES SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer (2002) 2(1):48-58.
60. MICHIELI M, DAMIANI D, ERMACORA A et al.: Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br. J. Haematol. (1999) 106(1):92-99.
61. RAHMAN A, HUSAIN SR, SIDDIQUI J et al.: Liposome-mediated modulation of multidrug resistance in human Hl-60 leukemia-cells. J. Natl. Cancer Inst. (1992) 84 24):1909-1915.
62. SADAVA D, COLEMAN A, KANE SE: Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J. Liposome Res. (2002) 12(4):301-309.
63. GOREN D, HOROWITZ AT, TZEMACH D et al.: Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. (2000) 6 5):1949-1957.
64. GABER MH: Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia. J. Biochem. Mol. Biol. Biophys. (2002) 6 5):309-314.
65. PAN XQ, WANG H, LEE RJ: Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm. Res. (2003) 20(3):417-422.
66. GABIZON A, HOROWITZ AT, GOREN D et al.: In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. (2003) 9(17):6551-6559.
67. JAIN RK: Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control. Release (2001) 74(1-3):7-25.
68. STRAUBINGER RM, ARNOLD RD, ZHOU R, MAZURCHUK R, SLACK JE: Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res. (2004) 24(2A):397-404.
69. ZHOU R, MAZURCHUK R, STRAUBINGER RM: Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res. (2002) 62(9):2561-2566.
70. CARMELIET P, JAIN RK: Angiogenesis in cancer and other diseases. Nature (2000) 407(6801):249-257.
71. HELMLINGER G, ENDO M, FERRARA N, HLATKY L, JAIN RK: Formation of endothelial cell networks. Nature (2000) 405 6783):139-141.
72. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86 3):353-364.
73. HOLASH J, MAISONPIERRE PC, COMPTON D et al.: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 284(5422):1994-1998.
74. FOLKMAN J: Angiogenesis and apoptosis. Semin. Cancer Biol. (2003) 13(2):159-167.
75. RATNAM M, HAO H, ZHENG X et al.: Receptor induction and targeted drug delivery: a new antileukaemia strategy. Expert Opin. Biol. Ther. (2003) 3(4):563-574.
76. WANG H, ZHENG X, BEHM FG, RATNAM M: Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood (2000) 96(10):3529-3536.
77. FELGNER PL, GADEK TR, HOLM M et al.: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA (1987) 84(21):7413-7417.
78. GAO X, HUANG L: Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry (1996) 35 3):1027-1036.
79. GAO X, HUANG L: Cationic liposome-mediated gene transfer. Gene Ther. (1995) 2(10):710-722.
80. LEE RJ, HUANG L: Lipidic vector system for gene transfer. Crit. Rev. Ther. Drug Carrier Syst. (1997) 14(2):173-206.
81. CHIU S-J, NI J, LEE RJ: Targeted gene delivery via the folate receptor, Chapter 33. In: Polymeric gene delivery: principles and applications. Amiji M (Ed.), CRC Press (2003):523-535.
82. WANG S, LOW PS: Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J. Control. Release (1998) 53(1-3):39-48.
83. REDDY JA, LOW PS: Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Syst. (1998) 15(6):587-627.
84. HOFLAND HE, MASSON C, IGINLA S et al.: Folate-targeted gene transfer in vivo. Mol. Ther. (2002) 5(6):739-744.
85. XU L, PIROLLO KF, CHANG EH: Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J. Control. Release (2001) 74(1-3):115-128.
86. REDDY JA, ABBURI C, HOFLAND H et al.: Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. (2002) 9(22):1542-1550.
87. REDDY JA, LOW PS: Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J. Control Release (2000) 64(1-3):27-37.
88. RAIT AS, PIROLLO KF, ULICK D, CULLEN K, CHANG EH: HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann. NY Acad. Sci. (2003) 1002:78-89.
89. RAIT AS, PIROLLO KF, XIANG L, ULICK D, CHANG EH: Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol. Med. (2002) 8(8):475-486.
90. PARK JW, HONG K, KIRPOTIN DB, PAPAHADJOPOULOS D, BENZ CC: Immunoliposomes for cancer treatment. Adv. Pharmacol. (1997) 40 399-435.